Versant Venture Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 12, 2026), Versant Venture Management, LLC reported 8 stock positions worth $162.6 million. Its top holding was Monte Rosa Therapeutics (GLUE) at 47.3% of the portfolio, followed by Century Therapeutics (IPSC, 18.3%) and Jade Biosciences (JBIO, 13.6%). Compared with Q1 2026, it reduced 1. The biggest sale was Jade Biosciences (JBIO, shares −35%).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001560009
- Portfolio Value
- $162.6M (Q2 2026)
- SEC Filing
- 0001193125-26-347068 ↗ filed Aug 12, 2026
Holdings Value
Holdings 8 stocks · $162.6M
| GLUE Monte Rosa Therapeutics Inc. | 47.34% | 3,180,780 | $77.0M | No change |
| IPSC Century Therapeutics Inc. | 18.33% | 12,166,109 | $29.8M | No change |
| JBIO Jade Biosciences Inc. | 13.55% | 991,783 | $22.0M | Reduce -35.0% |
| LENZ Lenz Therapeutics Inc. | 9.28% | 2,656,888 | $15.1M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 5.47% | 542,628 | $8.9M | No change |
| CRSP Crispr Therapeutics AG | 4.99% | 148,831 | $8.1M | No change |
| SKYE Skye Bioscience Inc. | 0.86% | 2,007,704 | $1.4M | No change |
| TPST Tempest Therapeutics Inc. | 0.18% | 269,772 | $299K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| JBIO Jade Biosciences Inc. | Reduce -35.0% | 13.55% | −1.61 |
Portfolio Buys Q1 2026 → Q2 2026
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 8 | $162.6M | GLUE, IPSC, JBIO, LENZ, CTNM |
| Q1 2026 | 8 | $141.4M | GLUE, IPSC, LENZ, JBIO, CTNM |
| Q4 2025 | 7 | $151.1M | GLUE, LENZ, JBIO, CRSP, CTNM |
| Q3 2025 | 9 | $212.5M | LENZ, GLUE, JBIO, CRSP, SKYE |
| Q2 2025 | 8 | $82.1M | GLUE, CRSP, JBIO, SKYE, RPTX |
| Q1 2025 | 7 | $60.2M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q4 2024 | 7 | $86.7M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q3 2024 | 6 | $63.6M | CRSP, CTNM, RPTX, SKYE, ADVM |
| Q2 2024 | 8 | $77.3M | CRSP, CTNM, SKYE, RPTX, ADVM |
| Q1 2024 | 7 | $103.1M | CRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM |